Literature DB >> 1905575

Pharmacokinetic studies of the nitroglycerin metabolites, 1,2- and 1,3- glyceryl dinitrates, in the rat.

D T Lau1, M Gumbleton, C Labisch, L Z Benet.   

Abstract

1,2- and 1,3-glyceryl dinitrates (1,2-GDN and 1,3-GDN) are the primary metabolites of glyceryl trinitrate, a commonly used anti-anginal agent. The goal of this study was to examine the pharmacokinetic properties of these metabolites in rats. Sprague-Dawley rats were infused intravenously with 0.25 or 2.0 micrograms min-1 of either 1,2- or 1,3-GDN for 70 min, during which steady state blood concentrations were achieved. Post-infusion blood samples were collected for 30 min. 1,2-GDN was found to possess slightly higher clearance (32.3 vs 20.8 ml min-1 kg-1) and volume of distribution (695 vs 454 ml kg-1) than 1,3-GDN; however, the two metabolites exhibited similar mean residence times (22.0 vs 21.8 min). Upon an 8-fold increase in the infusion rate, the pharmacokinetic parameters were not significantly altered for either 1,2- or 1,3-GDN. When each GDN was co-infused with an 8-fold higher dose of the other GDN, there were also no significant changes in the parameters.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1905575     DOI: 10.1002/bdd.2510120306

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  3 in total

1.  Vascular and anti-platelet actions of 1,2- and 1,3-glyceryl dinitrate.

Authors:  D Salvemini; A Pistelli; E Anggard
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

2.  Variable glyceryl dinitrate formation following infusions of glyceryl trinitrate at different vascular sites in the rat.

Authors:  E Nakashima; D T Lau; L Z Benet
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

Review 3.  Organic nitrate metabolism and action: toward a unifying hypothesis and the future-a dedication to Professor Leslie Z. Benet.

Authors:  Nathaniel A Page; Ho-Leung Fung
Journal:  J Pharm Sci       Date:  2013-05-13       Impact factor: 3.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.